Loading...

InterCure Ltd.

INCR•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$1.55
$0.01(0.65%)

InterCure Ltd. (INCR) AI-Powered Stock Analysis

See how InterCure Ltd. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full Disclaimer

InterCure Ltd. (INCR) Stock Overall Grade

InterCure Ltd.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

B

Good

Grade Breakdown by Metric

See how each financial and market factor contributes to InterCure Ltd.'s overall stock rating.

Forecast

C+

Score

55/100

Financial Growth

C

Score

40/100

Fundamental Growth

C+

Score

51/100

Key Ratios

C+

Score

55/100

Sector Comparison

B+

Score

75/100

Industry Comparison

B+

Score

75/100

S&P 500 Benchmark

A

Score

85/100

Analyst Consensus

C+

Score

50/100

InterCure Ltd. (INCR) AI-Powered Stock Analysis

This asset demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.

Component Analysis Explained

Understand the key factors behind each InterCure Ltd. stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions

;